Drug benefit-risk (BR) analysis is based on firm clinical evidence regarding various safety and efficacy outcomes. In this paper, we propose a new and more formal approach for constructing a supporting multicriteria model that fully takes into account the evidence on efficacy and adverse drug reactions. Our approach is based on the stochastic multi-criteria acceptability analysis methodology, which allows us to compute the typical value judgments that support a decision, to quantify decision uncertainty, and to compute a comprehensive BR profile. We construct a multi-criteria model for the therapeutic group of second-generation antidepressants. We assess fluoxetine and venlafaxine together with placebo according to incidence of treatment re...
Clinical trials generally allow various efficacy and safety outcomes to be collected for health inte...
Quantitative methodologies have been proposed to support decision making in drug development and mo...
Objectives : To test the ability of a multi-criteria decision analysis (MCDA) model to incorporate d...
Drug benefit-risk (BR) analysis is based on firm clinical evidence regarding various safety and effi...
Drug benefit-risk analysis is based on firm clinical evidence related to various safety and efficacy...
Quantitative methodologies have been proposed to support decision making in drug development and mon...
Multi-criteria decision analysis is a quantitative approach to the drug benefit–risk assessment whic...
AbstractBackgroundThe Problem formulation, Objectives, Alternatives, Consequences, Trade-offs, Uncer...
AbstractObjectiveTo enable multicriteria benefit–risk (BR) assessment of any number of alternative t...
Purpose One of the most important uses of benefit-risk assessment pertains to approval of new medic...
Decision makers in different health care settings need to weigh the benefits and harms of alternativ...
Objective: To enable multicriteria benefit risk (BR) assessment of any number of alternative treatme...
The approval process for pharmaceuticals has always included a consideration of the trade-offs betwe...
Clinical trials generally allow various efficacy and safety outcomes to be collected for health inte...
Quantitative methodologies have been proposed to support decision making in drug development and mo...
Objectives : To test the ability of a multi-criteria decision analysis (MCDA) model to incorporate d...
Drug benefit-risk (BR) analysis is based on firm clinical evidence regarding various safety and effi...
Drug benefit-risk analysis is based on firm clinical evidence related to various safety and efficacy...
Quantitative methodologies have been proposed to support decision making in drug development and mon...
Multi-criteria decision analysis is a quantitative approach to the drug benefit–risk assessment whic...
AbstractBackgroundThe Problem formulation, Objectives, Alternatives, Consequences, Trade-offs, Uncer...
AbstractObjectiveTo enable multicriteria benefit–risk (BR) assessment of any number of alternative t...
Purpose One of the most important uses of benefit-risk assessment pertains to approval of new medic...
Decision makers in different health care settings need to weigh the benefits and harms of alternativ...
Objective: To enable multicriteria benefit risk (BR) assessment of any number of alternative treatme...
The approval process for pharmaceuticals has always included a consideration of the trade-offs betwe...
Clinical trials generally allow various efficacy and safety outcomes to be collected for health inte...
Quantitative methodologies have been proposed to support decision making in drug development and mo...
Objectives : To test the ability of a multi-criteria decision analysis (MCDA) model to incorporate d...